Loading…
Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76
Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. We examined the relati...
Saved in:
Published in: | Diabetologia 2006-12, Vol.49 (12), p.2892-2899 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3 |
container_end_page | 2899 |
container_issue | 12 |
container_start_page | 2892 |
container_title | Diabetologia |
container_volume | 49 |
creator | CALLE, R MCCARTHY, M. I MANCUSO, J MILOS, P FRYBURG, D HOLMAN, R. R BANERJEE, P ZEGGINI, E CULL, C. A THORNE, K. I WILTSHIRE, S TERRA, S MEYER, D RICHMOND, J |
description | Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes.
We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors.
rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus.
We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes. |
doi_str_mv | 10.1007/s00125-006-0436-8 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68139521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68139521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxUOxtGv1D_BFgmCxD1NvMpl89E3a2orFLmjBt5DJB06ZScZkpnT_e2fZhYJPl8v5nQP3HoTeETgnAOJzASC0qQB4BazmlTxAK8JqumxUvkKrrVwRyX8fo9elPAJA3TB-hI6JAMUJkSvk1yab9JyiKR5T_Gl9_4Oe4TH1myHl8U9XhoJNdNj5J9-ncfBxwing7KPpsduUMEc7dSniLuJpM24zXGdaP_mCL_DD9_XVTyz4G3QYTF_82_08QQ9fr39d3lZ39zffLr_cVbZWaqqkAhcaDuCElOCtIybUAogH2xBHhGqFCtDY0FJuFGHApWRgfGBOGQptfYJOd7ljTn9nXyY9dMX6vjfRp7loLkmtGkoW8MN_4GOa83JT0YsqmWCcLRDZQTanUrIPeszdYPJGE9DbAvSuAL0UoLcFaLl43u-D53bw7sWx__gCfNwDpljTh2yi7coLJ6lSgrL6H0u2i0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213847464</pqid></control><display><type>article</type><title>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</title><source>Springer Link</source><creator>CALLE, R ; MCCARTHY, M. I ; MANCUSO, J ; MILOS, P ; FRYBURG, D ; HOLMAN, R. R ; BANERJEE, P ; ZEGGINI, E ; CULL, C. A ; THORNE, K. I ; WILTSHIRE, S ; TERRA, S ; MEYER, D ; RICHMOND, J</creator><creatorcontrib>CALLE, R ; MCCARTHY, M. I ; MANCUSO, J ; MILOS, P ; FRYBURG, D ; HOLMAN, R. R ; BANERJEE, P ; ZEGGINI, E ; CULL, C. A ; THORNE, K. I ; WILTSHIRE, S ; TERRA, S ; MEYER, D ; RICHMOND, J</creatorcontrib><description>Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes.
We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors.
rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus.
We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-006-0436-8</identifier><identifier>PMID: 17096118</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Albuminuria - genetics ; Amino Acid Substitution ; Aryldialkylphosphatase - genetics ; Associated diseases and complications ; Biological and medical sciences ; Blood Pressure ; Cardiovascular disease ; Creatinine ; Creatinine - blood ; Creatinine - urine ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - enzymology ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - enzymology ; Diabetic Nephropathies - genetics ; Diabetic nephropathy ; Disease Progression ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Ethnic Groups ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Genotype ; Humans ; Kidneys ; Laboratories ; Linkage Disequilibrium ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Oxidative stress ; Plasma ; Polymorphism, Genetic ; Polymorphism, Single Nucleotide ; R&D ; Research & development ; Urinary system involvement in other diseases. Miscellaneous</subject><ispartof>Diabetologia, 2006-12, Vol.49 (12), p.2892-2899</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</citedby><cites>FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18299724$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17096118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CALLE, R</creatorcontrib><creatorcontrib>MCCARTHY, M. I</creatorcontrib><creatorcontrib>MANCUSO, J</creatorcontrib><creatorcontrib>MILOS, P</creatorcontrib><creatorcontrib>FRYBURG, D</creatorcontrib><creatorcontrib>HOLMAN, R. R</creatorcontrib><creatorcontrib>BANERJEE, P</creatorcontrib><creatorcontrib>ZEGGINI, E</creatorcontrib><creatorcontrib>CULL, C. A</creatorcontrib><creatorcontrib>THORNE, K. I</creatorcontrib><creatorcontrib>WILTSHIRE, S</creatorcontrib><creatorcontrib>TERRA, S</creatorcontrib><creatorcontrib>MEYER, D</creatorcontrib><creatorcontrib>RICHMOND, J</creatorcontrib><title>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><description>Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes.
We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors.
rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus.
We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.</description><subject>Albuminuria - genetics</subject><subject>Amino Acid Substitution</subject><subject>Aryldialkylphosphatase - genetics</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure</subject><subject>Cardiovascular disease</subject><subject>Creatinine</subject><subject>Creatinine - blood</subject><subject>Creatinine - urine</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - enzymology</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - enzymology</subject><subject>Diabetic Nephropathies - genetics</subject><subject>Diabetic nephropathy</subject><subject>Disease Progression</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Ethnic Groups</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Genotype</subject><subject>Humans</subject><subject>Kidneys</subject><subject>Laboratories</subject><subject>Linkage Disequilibrium</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oxidative stress</subject><subject>Plasma</subject><subject>Polymorphism, Genetic</subject><subject>Polymorphism, Single Nucleotide</subject><subject>R&D</subject><subject>Research & development</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpdkd1rFDEUxUOxtGv1D_BFgmCxD1NvMpl89E3a2orFLmjBt5DJB06ZScZkpnT_e2fZhYJPl8v5nQP3HoTeETgnAOJzASC0qQB4BazmlTxAK8JqumxUvkKrrVwRyX8fo9elPAJA3TB-hI6JAMUJkSvk1yab9JyiKR5T_Gl9_4Oe4TH1myHl8U9XhoJNdNj5J9-ncfBxwing7KPpsduUMEc7dSniLuJpM24zXGdaP_mCL_DD9_XVTyz4G3QYTF_82_08QQ9fr39d3lZ39zffLr_cVbZWaqqkAhcaDuCElOCtIybUAogH2xBHhGqFCtDY0FJuFGHApWRgfGBOGQptfYJOd7ljTn9nXyY9dMX6vjfRp7loLkmtGkoW8MN_4GOa83JT0YsqmWCcLRDZQTanUrIPeszdYPJGE9DbAvSuAL0UoLcFaLl43u-D53bw7sWx__gCfNwDpljTh2yi7coLJ6lSgrL6H0u2i0c</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>CALLE, R</creator><creator>MCCARTHY, M. I</creator><creator>MANCUSO, J</creator><creator>MILOS, P</creator><creator>FRYBURG, D</creator><creator>HOLMAN, R. R</creator><creator>BANERJEE, P</creator><creator>ZEGGINI, E</creator><creator>CULL, C. A</creator><creator>THORNE, K. I</creator><creator>WILTSHIRE, S</creator><creator>TERRA, S</creator><creator>MEYER, D</creator><creator>RICHMOND, J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</title><author>CALLE, R ; MCCARTHY, M. I ; MANCUSO, J ; MILOS, P ; FRYBURG, D ; HOLMAN, R. R ; BANERJEE, P ; ZEGGINI, E ; CULL, C. A ; THORNE, K. I ; WILTSHIRE, S ; TERRA, S ; MEYER, D ; RICHMOND, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Albuminuria - genetics</topic><topic>Amino Acid Substitution</topic><topic>Aryldialkylphosphatase - genetics</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure</topic><topic>Cardiovascular disease</topic><topic>Creatinine</topic><topic>Creatinine - blood</topic><topic>Creatinine - urine</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - enzymology</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - enzymology</topic><topic>Diabetic Nephropathies - genetics</topic><topic>Diabetic nephropathy</topic><topic>Disease Progression</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Ethnic Groups</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Genotype</topic><topic>Humans</topic><topic>Kidneys</topic><topic>Laboratories</topic><topic>Linkage Disequilibrium</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oxidative stress</topic><topic>Plasma</topic><topic>Polymorphism, Genetic</topic><topic>Polymorphism, Single Nucleotide</topic><topic>R&D</topic><topic>Research & development</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CALLE, R</creatorcontrib><creatorcontrib>MCCARTHY, M. I</creatorcontrib><creatorcontrib>MANCUSO, J</creatorcontrib><creatorcontrib>MILOS, P</creatorcontrib><creatorcontrib>FRYBURG, D</creatorcontrib><creatorcontrib>HOLMAN, R. R</creatorcontrib><creatorcontrib>BANERJEE, P</creatorcontrib><creatorcontrib>ZEGGINI, E</creatorcontrib><creatorcontrib>CULL, C. A</creatorcontrib><creatorcontrib>THORNE, K. I</creatorcontrib><creatorcontrib>WILTSHIRE, S</creatorcontrib><creatorcontrib>TERRA, S</creatorcontrib><creatorcontrib>MEYER, D</creatorcontrib><creatorcontrib>RICHMOND, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CALLE, R</au><au>MCCARTHY, M. I</au><au>MANCUSO, J</au><au>MILOS, P</au><au>FRYBURG, D</au><au>HOLMAN, R. R</au><au>BANERJEE, P</au><au>ZEGGINI, E</au><au>CULL, C. A</au><au>THORNE, K. I</au><au>WILTSHIRE, S</au><au>TERRA, S</au><au>MEYER, D</au><au>RICHMOND, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</atitle><jtitle>Diabetologia</jtitle><addtitle>Diabetologia</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>49</volume><issue>12</issue><spage>2892</spage><epage>2899</epage><pages>2892-2899</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes.
We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors.
rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus.
We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>17096118</pmid><doi>10.1007/s00125-006-0436-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-186X |
ispartof | Diabetologia, 2006-12, Vol.49 (12), p.2892-2899 |
issn | 0012-186X 1432-0428 |
language | eng |
recordid | cdi_proquest_miscellaneous_68139521 |
source | Springer Link |
subjects | Albuminuria - genetics Amino Acid Substitution Aryldialkylphosphatase - genetics Associated diseases and complications Biological and medical sciences Blood Pressure Cardiovascular disease Creatinine Creatinine - blood Creatinine - urine Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - enzymology Diabetes Mellitus, Type 2 - genetics Diabetes. Impaired glucose tolerance Diabetic Nephropathies - blood Diabetic Nephropathies - enzymology Diabetic Nephropathies - genetics Diabetic nephropathy Disease Progression Endocrine pancreas. Apud cells (diseases) Endocrinopathies Ethnic Groups Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Genotype Humans Kidneys Laboratories Linkage Disequilibrium Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Oxidative stress Plasma Polymorphism, Genetic Polymorphism, Single Nucleotide R&D Research & development Urinary system involvement in other diseases. Miscellaneous |
title | Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T06%3A21%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paraoxonase%202%20(PON2)%20polymorphisms%20and%20development%20of%20renal%20dysfunction%20in%20type%202%20diabetes%20:%20UKPDS%2076&rft.jtitle=Diabetologia&rft.au=CALLE,%20R&rft.date=2006-12-01&rft.volume=49&rft.issue=12&rft.spage=2892&rft.epage=2899&rft.pages=2892-2899&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-006-0436-8&rft_dat=%3Cproquest_cross%3E68139521%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213847464&rft_id=info:pmid/17096118&rfr_iscdi=true |